argenx SE – (ARGX) Shares Sold by Dorsey Wright & Associates

Dorsey Wright & Associates trimmed its stake in shares of argenx SE – (NASDAQ:ARGX) by 33.3% during the third quarter, Holdings Channel reports. The fund owned 62,861 shares of the company’s stock after selling 31,317 shares during the quarter. Dorsey Wright & Associates’ holdings in argenx were worth $4,767,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ARGX. Aperio Group LLC bought a new position in argenx during the 1st quarter valued at $268,000. Northern Trust Corp bought a new position in shares of argenx in the 1st quarter worth about $896,000. Dimensional Fund Advisors LP bought a new position in shares of argenx in the 1st quarter worth about $498,000. Barclays PLC bought a new position in shares of argenx in the 1st quarter worth about $2,953,000. Finally, Jane Street Group LLC bought a new position in shares of argenx in the 1st quarter worth about $619,000. Hedge funds and other institutional investors own 56.14% of the company’s stock.

argenx stock opened at $72.69 on Friday. argenx SE – has a 1 year low of $22.21 and a 1 year high of $103.00. The stock has a market capitalization of $2.44 billion, a PE ratio of -51.92 and a beta of 2.43.

A number of research firms have recently issued reports on ARGX. Nomura began coverage on shares of argenx in a research report on Friday, June 29th. They issued a “buy” rating and a $161.00 price target on the stock. Wedbush raised their price target on shares of argenx from $93.00 to $114.00 and gave the stock an “outperform” rating in a research report on Monday, June 25th. JMP Securities raised their price target on shares of argenx from $93.00 to $130.00 and gave the stock a “positive” rating in a research report on Monday, June 18th. SunTrust Banks raised their price target on shares of argenx to $132.00 and gave the stock an “in-line” rating in a research report on Tuesday, September 18th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $139.00 price target on shares of argenx in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $133.43.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: Analyzing a company’s cash flow statement

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply